Sign in
Taking peoplePhase 2

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)

Key facts

Who runs it
Heidelberg University Hospital AöR
Where
Austria and Germany17 sites in 2 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
64 people, planned
Started
15 Nov 2023
Expected to end
1 Dec 2028
Type of study
Interventional
Record updated
9 September 2026

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Definite diagnosis of TSC according to the 2021 Updated International Tuberous Sclerosis Complex Diagnostic Criteria
  • <4 months of age at the time of enrolment (randomization and treatment initiation must occur before 4 months of age; infants born prematurely must have a corrected age of at least 39 weeks, calculated by subtracting the number of weeks born before 40 weeks gestation from the actual chronological age, in weeks)
  • Signed informed consent from legal guardian(s) prior to any study specific procedure

Who cannot take part

  • Has been treated in the past or is currently being treated at the time of enrolment with systemic mTOR inhibitors (such as rapamycin, sirolimus, or everolimus)
  • Has a TSC-associated condition for which mTOR treatment is clinically indicated, i.e. subependymal giant cell astrocytoma (SEGA)
  • Contraindication to study medication. Rapamune® oral solution contains soya oil. Patients allergic to peanut or soya must not take this medicine
  • Abnormal laboratory values at screening (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject
  • History of significant prematurity, defined as gestational age < 30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that, apart from TSC, would convey additional risk of seizures or neurodevelopmental delay (i.e. hypoxic ischemic encephalopathy (HIE), severe neonatal infection, major surgery, prolonged ventilatory or other lifesaving supportive care or procedures)
  • Current enrolment, or observation period of competing clinical trials at any time during enrolment in the study
  • Parents / caregiver of the child who are, in the opinion of the investigator, unable to comply with the requirements of the study

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Neuropsychologic outcome at 24 months of age assessed by rater blinded neuropsychologic testing measured by the cognitive scale on the Bayley Scales of Infant and Toddler Development III (BSID-III) compared with Standard of Care (SOC) alone.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
9 September 2026